Table 2: Reports submitted to Health Canada on types of suspected cardiovascular/cerebrovascular ARs associated with selective COX-2 inhibitors from date marketed to Oct. 12, 2001*

Drug; no. of reactions

Type of reaction	Celecoxib	Rofecoxib	Meloxicam
Increased blood pressure	20	21	1
Congestive heart failure	7	17	-
Myocardial infarction†	8	9	1
Angina	-	2	-
Heart rate and rhythm disorders‡	24	20	-
Cerebrovascular events due to hemorrhage or cause non specified§	9	9	-
Cerebrovascular events with clot	1	-	-
Thromboembolic events¶	8	-	-
Pericardial effusion	1	-	-
Endocarditis	1	-	-
Aortic aneurysm rupture	1	-	-
Vasculitis	3	-	-

*This table reports reactions, and each report may contain more than 1 reaction. These data cannot be used to determine the incidence of ARs because neither patient exposure nor the amount of time the drug was on the market has been taken into consideration.
†Includes myocardial ischemia.
‡Includes cardiac arrest, cardiac arrhythmia, atrial fibrillation, ventricular fibrillation, heart block, sick sinus syndrome, tachycardia, ventricular tachycardia, palpitation, bradycardia.
§Includes cerebrovascular accident, stroke, transient ischemic attack.
¶Includes pulmonary embolism, deep vein thrombosis, venous arm thrombosis, limb embolism, peripheral ischemia.